Pituit ary tumors account for approximately 15% of all intracranial neoplasms. They can beeither benign or malignant, primary or secondary, and epithelial or nonepithelial. Pituitary carcinoma can only be diagnosed when there is confirmed meta static disease.The vast majority are primary epithelial pituitary adenomas, which generally arise from hormon e-producing cells , regardless ofwhether a particular tumor is active or inactive (i.e., non-hormone-producing). Pituitary adenomas are further cla ssified on the basi s of size, function , cell type , hormone production, location, and biologic beh avior. Most pituitary adenomas are benign neoplasms, either null-cell or prolactin-producing microadenomas «I em in their gre atest dimension-usually seen radiographically) that are seen within the pituitary gland. Most pituitary adenomas occur in women; they can ari se at any age , but they are more common in the third through sixth decades of life . Patient s with a pituitary adenoma present with e ither an end ocrin opathy or a mass effect. Nonfunctioning adenomas exhibit no biochemical or clinical evidence of excess ive hormone production. Patients with functional tumors present with specific syndromes, such as Cu shing's syndro me (adrenocorticotropic hormone-producing).
Histologically, pituitary adenomas are classi fied as basophilic, eosinophilic, and null cell; eac h has a host of differe nt subtypes whose classificati on is based on speci fic ultrastru ctural and immunophenotypic fea tures . Cell s are usually arranged in sheets or in gland-like or folli cular struc tures (figure 1). The size of the cells varies from small to medium. Some cells have eos inophilic to basophili c granular cytoplasm, and others have clear cytoplasm (figure 2). Immunophenotypically, these cells reac t with keratin, chro mogranin, and synaptophys in; they also dem onstrate spec ific peptid es in many cases . The transsph enoid appr oach to surgical excision is the most effec tive treatment , with a cure rate that ranges fro m 75 to 93 %. Irrad iation has also bee n used ; among adults, its cure rate is 15% and its clini cal imp rovement rate is 30 %. Specific sy mptoms ca used by functional tumors ca n be managed with pharm acotherapy, but with mixe d result s. 
